Novartis psoriasis drug bests Enbrel in trial


Novartis' (NVS +0.1%) IL-17A inhibitor secukinumab cleared skin faster and for longer than Enbrel (AMGN -0.9%) in a Phase 3 plaque psoriasis study.

FIXTURE met all primary and secondary endpoints.

Here's NVS' head of pharmaceuticals with the no-frills take: "These exciting data suggest that with secukinumab, we have the potential to help more patients achieve clear skin, which is the ultimate treatment goal."

Expect regulatory submissions later this year in both the U.S. and Europe. (PR)

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs